Business, energy, technology, markets and global industry news from Business News Today

Sotyktu

PharmaDeviceNews Sotyktu
Representative image: A clinical consultation for psoriatic arthritis, highlighting how Bristol Myers Squibb’s EU approval of Sotyktu could expand oral treatment options for adults with active inflammatory joint disease.
Pharma & Biotech

Why Bristol Myers Squibb’s Sotyktu approval could reshape the oral psoriatic arthritis race

A new EU approval is only the first hurdle. Sotyktu now faces Europe’s tougher test: payer access, sequencing, and real-world uptake.

Read More
Pharma & Biotech

Can Takeda’s zasocitinib change the plaque psoriasis treatment ladder after Phase 3 wins?

Takeda’s zasocitinib posted strong Phase 3 psoriasis data. Read what it changes for TYK2 competition, regulation, and oral treatment strategy.

Read More
Bristol Myers Squibb wins FDA approval for Sotyktu in psoriatic arthritis. What it means for oral autoimmune therapies
Pharma & Biotech

Bristol Myers Squibb expands Sotyktu label. Will TYK2 inhibition challenge biologics in psoriatic arthritis?

FDA approves Bristol Myers Squibb’s Sotyktu for psoriatic arthritis. Discover what TYK2 inhibition means for autoimmune treatment and future rheumatology drugs.

Read More